Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease

Digestive and Liver Disease

Volumn 43, Issue 1, 2011, Pages 73-77

  Bianchi, Giampaolo ^a   Bugianesi, Elisabetta ^b   Frystyk, Jan ^c   Tarnow, Lise ^d   Flyvbjerg, Allan ^c   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d STENO DIABETES CENTER   (Denmark)

Author keywords

Adiponectin; Fatty liver; Insulin resistance; Liver disease

Indexed keywords

ADIPONECTIN;

ADULT; ANTHROPOMETRY; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEX RATIO;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; FATTY LIVER; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROTEIN ISOFORMS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 78649950656     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.05.011     Document Type: Article

References (47)

1. Falck-Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21:17-26.
2. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
3. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
4. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
5. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
6. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
7. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
8. Bugianesi E., Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004, 39:179-187.
9. Scherer P.E., Williams S., Fogliano M., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
10. Bajaj M., Suraamornkul S., Piper P., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:200-206.
11. Lopez-Bermejo A., Botas P., Funahashi T., et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004, 60:256-263.
12. Yokoyama H., Hirose H., Ohgo H., et al. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004, 41:19-24.
13. Andersen K.K., Frystyk J., Wolthers O.D., et al. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007, 92:1857-1862.
14. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
15. Waki H., Yamauchi T., Kamon J., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278:40352-40363.
16. Wang Y., Lam K.S., Yau M.H., et al. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008, 409:623-633.
17. Leth H., Andersen K.K., Frystyk J., et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab 2008, 93:3186-3191.
18. Pajvani U.B., Du X., Combs T.P., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073-9085.
19. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
20. Musso G., Gambino R., De Michieli F., et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NAFLD. Hepatology 2008, 46:1167-1177.
21. Adachi M., Brenner D.A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008, 47:677-685.
22. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
23. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
24. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
25. Mari A., Pacini G., Murphy E., et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24:539-548.
26. Bugianesi E., Pagotto U., Manini R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005, 90:3498-3504.
27. Frystyk J., Tarnow L., Hansen T.K., et al. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48:1911-1918.
28. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
29. Tabara Y., Osawa H., Kawamoto R., et al. Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the shimanami health promoting program study. J Clin Endocrinol Metab 2008, 93:715-722.
30. Schober F., Neumeier M., Weigert J., et al. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochem Biophys Res Commun 2007, 361:968-973.
31. Salani B., Briatore L., Andraghetti G., et al. High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity (Silver Spring, MD) 2006, 14:1511-1514.
32. Engl J., Sturm W., Sandhofer A., et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest 2008, 38:238-244.
33. Tomizawa A., Hattori Y., Kasai K., et al. Adiponectin induces NF-kappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res 2008, 5:123-127.
34. Bodles A.M., Banga A., Rasouli N., et al. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006, 291:E1100-1105.
35. Qurashi S., Mynarcik D.C., McNurlan M.A., et al. Importance of the high molecular weight isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clin Sci (Lond) 2008.
36. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
37. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
38. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
39. Kato K., Osawa H., Ochi M., et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf) 2008, 68:442-449.
40. Komura N., Kihara S., Sonoda M., et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008, 72:23-28.
41. Nakatani H., Hirose H., Yamamoto Y., et al. Significance of leptin and high-molecular weight adiponectin in the general population of Japanese male adolescents. Metabolism 2008, 57:157-162.
42. Tsuda S., Nakano S., Konishi K., et al. A lack of increase in high molecular weight-adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks. Diabetes Res Clin Pract 2008, 79:503-509.
43. von Eynatten M., Humpert P.M., Bluemm A., et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008, 199:123-128.
44. Svegliati-Baroni G., Bugianesi E., Bouserhal T., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007, 56:1296-1301.
45. Mari A., Pacini G., Brazzale A.R., et al. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005, 48:748-751.
46. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008, 51:1781-1789.
47. Okamoto Y., Kihara S., Funahashi T., et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278.